Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant ALK-Positive NSCLC

NCT07671560 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

80

Enrollment

OTHER_GOV

Sponsor class

Conditions

ALK-positive, Locally Advanced or Metastatic (TNM Stage IIIB-IV) Non-small Cell Lung Cancer That Has Developed Resistance to Prior Treatment With Lorlatinib

Interventions

DRUG: Combined group of ensatinib and arotinib

Sponsor

Qiming Wang

Collaborators

[object Object]